|Dear U.S. Pain Foundation advocates, |
We wanted to let you know about an opportunity to take action on a federal bill that would expand and coordinate scientific research of cannabidiol (CBD) or marijuana-derived products, allowing researchers to better understand their potential efficacy and safety. While medical cannabis is increasingly available in a number of states nationwide, too often, there is little clinical data available to help patients and health care providers make informed decisions about whether it would work well for their specific condition, or how much and what type to use. Introduced by Senators Dianne Feinstein, Chuck Grassley, and Brian Schatz, The Cannabidiol and Marihuana Research Expansion Act (S. 2032) would streamline the research process, eliminating the lengthy delays and roadblocks researchers face when trying to study medical marijuana and CBD-derived products. Why U.S. Pain supports S. 2032
We believe people with chronic illness and pain should have access to all safe, effective treatments, including medical cannabis. Research is critical as it would lead to increased understanding about cannabis as a therapeutic option (including efficacy, safety, proper dosing, best delivery methods, etc.) and may lead to new, FDA-approved treatment options for people with pain. Now is the time to take action
U.S. Pain has created two online campaigns for advocates on this issue because we’d like to accomplish two goals: 1. Have the Senate Committee on the Judiciary schedule a hearing on the bill2. Gain additional cosponsors of the bill Click here and see if your Senator sits on the Committee on the Judiciary. If they do, use the button below.
Urge your Senator to hold a hearing >> If your Senator doesn’t sit on the committee, you can still help support medical marijuana and CBD research by requesting he/she becomes a cosponsor.Get your Senator to cosponsor the bill >>To learn more about U.S. Pain’s views on medical cannabis, read our position statement here.
Thank you for supporting us as we fight to open up research opportunities surrounding complementary and integrative therapy options for people with pain.
Ellen Lenox Smith
Co-Director for Medicinal CannabisU.S. Pain Foundation